Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Metformin, a widely used and affordable diabetes drug, could prevent a form of acute myeloid leukemia in people at high risk ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly ...

A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid Leukemia (AML) with GPC-100. The company believes that GPC-100, when paired with modern AML treatment regimens ...

The purpose of the present study was to investigate whether expression levels of adenylate kinase 1 (AK1) were associated with prognosis of acute myeloid leukemia (AML) in patients treated with ...